Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-SibuDAB
- Development stage
- Unknown
- Lead developer
- Paul Scherrer Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
177Lu-SibuDAB (also known as 177Lu-(S)-Ibu-DAB-PSMA) is an investigational, albumin-binding radioligand therapy developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Developed by the Paul Scherrer Institute (PSI) in collaboration with ITM Isotope Technologies Munich, the compound consists of a urea-based prostate-specific membrane antigen (PSMA)-targeting ligand conjugated to an (S)-ibuprofen moiety via a diaminobutyric acid (DAB) linker, radiolabeled with the beta-emitting isotope lutetium-177 (177Lu). The (S)-ibuprofen component acts as a weak-to-moderate albumin binder, which prolongs blood circulation and enhances tumor accumulation and retention compared to conventional radioligands like 177Lu-PSMA-617, while maintaining a favorable safety profile with reduced salivary gland uptake (preventing xerostomia) and manageable kidney clearance.
- Other names
- 177Lu-(S)-Ibu-DAB-PSMA[177Lu]Lu-SibuDABlutetium (177Lu) SibuDABlutetium Lu 177 SibuDABlutetium-177 SibuDABlutetium177 SibuDABlutetium 177 SibuDAB
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 177Lu-SibuDAB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-SibuDAB.